Eli Lilly to buy Centessa Pharma in $6.3 billion deal

[Jaybee00]

Eli Lilly to buy Centessa Pharma in $6.3 billion deal

March 31 () - ‌Eli ‌Lilly said on Tuesday ‌it ⁠would ⁠buy Centessa Pharmaceuticals in ‌a deal ‌worth about $6.3 billion to ‌advance treatments for sleep-wake disorders.

finance.yahoo.com

The acquisition gives Lilly ownership of Centessa’s orexin receptor 2 (OX2R) agonist pipeline, including cleminorexton, described as a “potential best-in-class therapeutic” for sleep-wake disorders such as narcolepsy types 1 and 2 and idiopathic hypersomnia.

The portfolio also includes several earlier-stage candidates with potential across broader neurological and neuropsychiatric conditions.

 

[Jaybee00]

Lilly Wakes Up Sleep Market With $6.3B Centessa Buy To Challenge Takeda

In the buyout, Eli Lilly picks up Centessa Pharmaceuticals’ lead asset cleminorexton, which could go toe-to-toe with Takeda’s oveporexton, currently under FDA review with a decision expected in the third quarter.

www.biospace.com

This drug delays sleep. Interesting….

“In April 2025, Centessa released Phase 1 datashowing that a 5-mg oral dose of cleminorexton delayed sleep by an average of 37.9 minutes compared to 15.3 minutes in placebo recipients, resulting in a “statistically significant” treatment effect of 22.6 minutes, the biotech said at the time.”